Contributions of von Willebrand factor to clinical severity of sickle cell disease: a systematic review and metanalysis

References

• Akaba K, Inyama M, Ekwere T, et al. Haemostatic disorders in sickle cell disease subjects in Nigeria: A review of literature. Int Blood Resour Rev. 2018;8:1–7.
   Google Scholar
• Clancy S. Genetic mutation. Nature Educ. 2008;1(1):187.
   Google Scholar
• Chen J, Hobbs WE, Le J, et al. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011;117:3680–3683.
   PubMed Web of Science ®Google Scholar
• Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107:2279–2285.
   PubMed Web of Science ®Google Scholar
• Akaba K, Nwogoh B, Oshatuyi O. Determination of von Willebrand factor level in patient with sickle cell disease in vaso-occlusive crisis. Res Practice Throm Hem. 2020;4:902–905.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology. 2007;1:91–96.
   Google Scholar
• Favaloro JE, Henrey BM, Lippi G. Covid-19 and antiphospholipid antibodies Time for a reality check? Seminar Throm Hem. 2022;48:72–92.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Han H, Cruz MA, et al. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost. 2009;101(6):1070–1077.
   PubMed Web of Science ®Google Scholar
• Omer NE, Maria M, Satti H, et al. Plasma level of von Willebrand factor: an indicator of severity in sickle cell disease. Sudan JMS. 2009;4(2). Doi:10.4314/sjms.v4i2.44897.
   Google Scholar
• Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010;115:706–712.
   PubMed Web of Science ®Google Scholar
• Ahmed SG, Kagu MB, Ibrahim UA. Correlation between ABO blood group and vaso-occlusive crisis among adult patients with sickle cell anaemia in northern Nigeria; 2010. Egyptian J Haematol. 2014;39:227–231.
   Google Scholar
• Studt JD, Kremer-Hovinga JA, Antoine G, et al. Fatal congenital thrombotic thrombocytopenic purpura with ADAMTS 13: in vitro inhibitor of ADAMTS 13 activity by haemoglobin. Blood. 2005;105:542–544.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Sys Rev. 2015;2015(4):1.
   Google Scholar
• Hong QN, Fàbregues S, Bartlett G, et al. The mixed methods appraisal tool (MMAT) version 2018 for information professionals and researchers. Educ Inf. 2018;34(4):285–291.
   Web of Science ®Google Scholar
• Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Higgins J, Thompson S, Deeks J, et al. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021.
   Google Scholar
• Demagny J, Aurélie D, Alain S, et al. ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso-occlusive crisis of sickle cell disease. Res Pract Thromb Haemost. 2021;5:197–203.
   PubMed Web of Science ®Google Scholar
• Mohan JS, Lip PL, Blann AD, et al. The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment. Br J Ophthalmol. 2005;89:815–819. doi: 10.1136/bjo.2004.058164.
   PubMed Web of Science ®Google Scholar
• Blanna AD, Marwah S, Serjeant G, et al. Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity. Blood Coagul Fibrin. 2003;14:255–259.
   PubMed Web of Science ®Google Scholar
• Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100(12):4033–4039. doi: 10.1182/blood-2002-05-1401.
   PubMed Web of Science ®Google Scholar
• Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99(11):3971–3977. doi: 10.1182/blood-2001-11-0060.
   PubMed Web of Science ®Google Scholar
• Mohandas N, Evans E. Sickle erythrocyte adherence to vascular endothelium: morphologic correlates and the requirement for divalent cations and collagen-binding plasma proteins. J Clin Invest. 1985;76(4):1605–1612.
   PubMed Web of Science ®Google Scholar
• Wick TM, Moake JL, Udden MM, et al. Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest. 1987;80(3):905–910.
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Suzuki H, McMullen B, et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98(6):1662–1666.
   PubMed Web of Science ®Google Scholar
• Browne PV, Mosher D, Steinberg MH, et al. Disturbances of plasma and platelet thrombospondin levels in Sickle cell anaemia. Am J Haematol. 1996;51:296–301.
   PubMed Web of Science ®Google Scholar
• Richardson SG, Mathews KB, Stuart J, et al. Serial changes in coagulation and viscosity during sickle cell crisis. Br J Haematol. 1979;41:95–103.
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Keung YK, Lopez-Arvizu C, et al. Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis. Ann Hematol. 1999;78(12):558–559.
   PubMed Web of Science ®Google Scholar
• Shelat SG. Thrombotic thrombocytopenic purpura and sickle cell crisis. Clin Appl Thromb Hemost. 2010;16(2):224–227.
   PubMed Web of Science ®Google Scholar
• Walmet PS, Eckman JR, Wick TM. Inflammatory mediators promote strong sickle cell adherence to endothelium under venular flow conditions. Am J Hematol. 2003;73(4):215–224.
   PubMed Web of Science ®Google Scholar
• Colombatti R, De Bon E, Bertomoro A, et al. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS ONE. 2013;8(10):e78801. doi:10.1371/journal.pone.0078801.
   PubMed Web of Science ®Google Scholar
• Sins JWR, Schimmel M, Luken BM, et al. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state. J Thromb Haemost. 2017;15(7):1392–1402. doi: 10.1111/jth.13728.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Siegel J, Pullen G, Jr, et al. Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thromb Res. 2008;122(4):455–458.
   PubMed Web of Science ®Google Scholar
• Inacio P. (2020). Inflammation Markers Identify Sickle Cell Patients at Risk for Worse Outcomes, Study Suggests. https://sicklecellanemianews.com/2020/03/31/inflammation-markers-identify-sickle-cell-patients-at-risk-of-worse-outcomes-study-suggests/.
   Google Scholar
• Domingos IF, Pereira-Martins DA, Sobreira MJVC, et al. High levels of proinflammatory cytokines IL-6 and IL-8 are associated with a poor clinical outcome in sickle cell anemia. Ann Hematol. 2020;99:947–953. https://doi.org/10.1007/s00277-020-03978-8.
   PubMed Web of Science ®Google Scholar